SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Dunlap who wrote (5932)3/17/1998 9:30:00 AM
From: Zebra 365  Read Replies (4) of 23519
 
Don,

You said, "The costs won't be recognized until the product is sold, and neither will the revenue."

This is wrong. If you read the billboard at the top of the thread, (which I wrote) VVUS recognizes revenue when product is shipped. They recognize costs as incurred. This is why the projections were for a loss in 1st quarter. Without MCA approval, they could produce (incurring extra costs) and not ship ie. (no revenues). The company projected a loss because they could not count on MCA approval as a certainty until it happened (shareholder lawsuits).

Now it has happened, First call will restate projected 1st quarter earnings and those of us buying at 10 and 11 recently are very happy.

Viagra is still a force to be reckoned with, but I expect at least a 2 point move today. Yes, sources tell me FDA has inspected but may be another month or two to approval. But they were doing fine with the current FDA approved facility, until they had to ship product to UK at lower margins.

Zebra
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News